TOT BIOPHARM International Company Limited (1875.HK)
HKD 1.89
(1.61%)
HKD 1.89
(1.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 739.41 Million CNY | 35.28% |
| 2022 | 546.59 Million CNY | 45.69% |
| 2021 | 375.17 Million CNY | 537.77% |
| 2020 | 58.82 Million CNY | -63.02% |
| 2019 | 159.08 Million CNY | -81.54% |
| 2018 | 861.71 Million CNY | 200.52% |
| 2017 | 286.74 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 732.76 Million CNY | 0.0% |
| 2023 Q2 | 708.21 Million CNY | 0.0% |
| 2023 Q4 | 739.41 Million CNY | 0.0% |
| 2023 FY | 739.41 Million CNY | 35.28% |
| 2022 FY | 546.59 Million CNY | 45.69% |
| 2022 Q2 | 484.1 Million CNY | 0.0% |
| 2022 Q4 | 601.33 Million CNY | 0.0% |
| 2021 Q4 | 375.17 Million CNY | 0.0% |
| 2021 FY | 375.17 Million CNY | 537.77% |
| 2021 Q2 | 152.22 Million CNY | 0.0% |
| 2020 FY | 58.82 Million CNY | -63.02% |
| 2020 Q4 | 58.82 Million CNY | 0.0% |
| 2020 Q2 | 69.84 Million CNY | 0.0% |
| 2019 Q4 | 159.08 Million CNY | 0.0% |
| 2019 FY | 159.08 Million CNY | -81.54% |
| 2018 FY | 861.71 Million CNY | 200.52% |
| 2017 FY | 286.74 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -383.853% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 89.524% |